2CARE, the Phase III trial for CoQ-10, has begun to enroll participants who have Huntington symptoms. 

Trial status: Phase III.

Sponsor: National Institutes of Health

Trial design: A randomized, double-blind, placebo controlled trial of high dose (2400 mg) CoQ-10 compared to placebo in 608 participants.  The trial is funded for five years, but will be stopped earlier if benefit is shown.

Location: Recruiting has begun in a portion of the 43 Huntington Study Group centers who are participating in this study.

Outcome measures: Comparison of UHDRS scores, functional capacity, and volumetric MRI brain scans before and after treatment.  The primary endpoint is functional capacity.